New Drug Association-Hanyang Securities to hold IR for excellent pharmaceutical and bio companies
Korea Drug Research Association (Chairman of the board: Dong-Yeon Kim) announced that 'Korea New Drug Development Research Association-Hanyang Securities Joint Bio Forum' was held on the 21st and 22nd at the Yeouido Korea Institute of financial investment and council chamber of Hanyang Securities.
The event aimed to create a healthy open innovation environment through discovery of promising ventures / startups and investment and cooperation between investment institutes and pharmaceutical and bio companies, building a smooth investment attraction environment and enhance the company's market value through a fair evaluation of R&D capabilities and performance inherent in pharmaceutical and bio companies.
On the first day of the IR event, Eutilex Co., Ltd., LegoChem Biosciences, Inc., Bioway Inc., and Biocure Pharm participated, and on the second day, Icure Pharm. Inc., Kanzen Biotechnology, Repure Life Science INC., and Pepgene participated.
In addition, the IR event announced the domestic and overseas pharmaceutical and bio industry trends of the Korea Drug Research Association Cho Heon-je, and introduced the IR business. The announcement followed.
Affiliates of union said that “The Korea Drug Research Association, an innovation-focused organization representing the Korean biohealth industry, has been attracting much attention and response from industry and institutional investors since 2015 by establishing a communication channel between companies and the capital market. It is expected to be more synergistic in strengthening the biohealth industry capital market linkage and activating promising startups.”